Literature DB >> 21384222

Latest approaches for the treatment of spasticity and autonomic dysreflexia in chronic spinal cord injury.

Alexander G Rabchevsky1, Patrick H Kitzman.   

Abstract

Two of the most prevalent secondary complications following spinal cord injury (SCI), besides loss of function and/or sensation below the level of injury, are uncontrolled muscle spasticity and hypertensive autonomic dysreflexia. Despite the desires of the SCI community, there have been few advances in the treatment and/or management of these fundamental impediments to the quality of life associated with chronic SCI. Therefore, the purpose of this review is to focus on current drug treatment strategies that alleviate symptoms of spasticity and autonomic dysfunction. Subsequently, looking ahead, we discuss whether individuals suffering from autonomic dysreflexia and/or muscle spasms can take certain compounds that specifically and rapidly block the neurotransmission of pain into the injured spinal cord to get rapid relief for both aberrant reflexes for which painful stimuli below the level of SCI are common precipitants.

Entities:  

Mesh:

Year:  2011        PMID: 21384222      PMCID: PMC3101828          DOI: 10.1007/s13311-011-0025-5

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  96 in total

Review 1.  Pain and spasticity after spinal cord injury: mechanisms and treatment.

Authors:  K J Burchiel; F P Hsu
Journal:  Spine (Phila Pa 1976)       Date:  2001-12-15       Impact factor: 3.468

Review 2.  Molecular mechanisms in the receptor action of benzodiazepines.

Authors:  E Costa; A Guidotti
Journal:  Annu Rev Pharmacol Toxicol       Date:  1979       Impact factor: 13.820

3.  Relationship between severity of spinal cord injury and abnormalities in neurogenic cardiovascular control in conscious rats.

Authors:  D N Maiorov; M G Fehlings; A V Krassioukov
Journal:  J Neurotrauma       Date:  1998-05       Impact factor: 5.269

4.  Psychological and emotional effects of the use of oral baclofen: a preliminary study.

Authors:  A Jamous; P Kennedy; C Psychol; N Grey
Journal:  Paraplegia       Date:  1994-05

5.  VGLUT1 and GLYT2 labeling of sacrocaudal motoneurons in the spinal cord injured spastic rat.

Authors:  Patrick Kitzman
Journal:  Exp Neurol       Date:  2006-11-28       Impact factor: 5.330

6.  Neutralizing intraspinal nerve growth factor blocks autonomic dysreflexia caused by spinal cord injury.

Authors:  N R Krenz; S O Meakin; A V Krassioukov; L C Weaver
Journal:  J Neurosci       Date:  1999-09-01       Impact factor: 6.167

7.  Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury.

Authors:  Funda Levendoglu; Cemile O Ogün; Onder Ozerbil; Tunç C Ogün; Hatice Ugurlu
Journal:  Spine (Phila Pa 1976)       Date:  2004-04-01       Impact factor: 3.468

8.  Neutralizing intraspinal nerve growth factor with a trkA-IgG fusion protein blocks the development of autonomic dysreflexia in a clip-compression model of spinal cord injury.

Authors:  Daniel R Marsh; Sharon T Wong; Susan O Meakin; James I S MacDonald; Eilis F Hamilton; Lynne C Weaver
Journal:  J Neurotrauma       Date:  2002-12       Impact factor: 5.269

9.  Plasticity of lumbosacral propriospinal neurons is associated with the development of autonomic dysreflexia after thoracic spinal cord transection.

Authors:  Shaoping Hou; Hanad Duale; Adrian A Cameron; Sarah M Abshire; Travis S Lyttle; Alexander G Rabchevsky
Journal:  J Comp Neurol       Date:  2008-08-01       Impact factor: 3.215

10.  Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors.

Authors:  G Pryce; D Baker
Journal:  Br J Pharmacol       Date:  2007-01-15       Impact factor: 8.739

View more
  33 in total

1.  Improving primary care for persons with spinal cord injury: Development of a toolkit to guide care.

Authors:  James Milligan; Joseph Lee; Loretta M Hillier; Karen Slonim; Catharine Craven
Journal:  J Spinal Cord Med       Date:  2018-05-07       Impact factor: 1.985

2.  An investigation of the relationship between autonomic dysreflexia and intrathecal baclofen in patients with spinal cord injury.

Authors:  Anna Sophia Del Fabro; Melvin Mejia; Gregory Nemunaitis
Journal:  J Spinal Cord Med       Date:  2017-04-13       Impact factor: 1.985

Review 3.  Psychiatric Evaluation and Management in Pediatric Spinal Cord Injuries: a Review.

Authors:  Jane Harness; Jessica Pierce; Nasuh Malas
Journal:  Curr Psychiatry Rep       Date:  2021-05-11       Impact factor: 5.285

4.  Neurotherapeutics. Editorial.

Authors:  Edward D Hall; Stephen M Onifer
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

5.  Management of Mental Health Disorders, Substance Use Disorders, and Suicide in Adults with Spinal Cord Injury: Clinical Practice Guideline for Healthcare Providers.

Authors:  Charles H Bombardier; Casey B Azuero; Jesse R Fann; Donald D Kautz; J Scott Richards; Sunil Sabharwal
Journal:  Top Spinal Cord Inj Rehabil       Date:  2021

Review 6.  The activity of the serotonin receptor 2C is regulated by alternative splicing.

Authors:  Stefan Stamm; Samuel B Gruber; Alexander G Rabchevsky; Ronald B Emeson
Journal:  Hum Genet       Date:  2017-06-29       Impact factor: 4.132

7.  Autonomic dysreflexia in spinal cord injury patients: an overview.

Authors:  Craig A Bauman; James D Milligan; F Joseph Lee; John J Riva
Journal:  J Can Chiropr Assoc       Date:  2012-12

8.  A Review of Spasticity Treatments: Pharmacological and Interventional Approaches.

Authors:  Eric Chang; Nilasha Ghosh; Daniel Yanni; Sujin Lee; Daniela Alexandru; Tahseen Mozaffar
Journal:  Crit Rev Phys Rehabil Med       Date:  2013

Review 9.  Chronic complications of spinal cord injury.

Authors:  Nebahat Sezer; Selami Akkuş; Fatma Gülçin Uğurlu
Journal:  World J Orthop       Date:  2015-01-18

10.  Prevention of recurrent autonomic dysreflexia: a survey of current practice.

Authors:  Deborah Caruso; David Gater; Christopher Harnish
Journal:  Clin Auton Res       Date:  2015-08-18       Impact factor: 4.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.